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Genetic factors contribute to an ill-defined proportion of breast cancer incidence, estimated to be about 5% of all cases but approximately 25% of cases diagnosed before age 30 (2) . Breast cancer has been subdivided into two types, early-onset and late-onset, a division that is based on an inflection in the age-specific incidence curve around age 50. Mutation of one gene, BRCA1, is thought to account for approximately 45% of families with significantly high breast cancer incidence and at least 80% of families with increased incidence of both early-onset breast cancer and ovarian cancer (3). Intense efforts to isolate the BRCA1 gene have proceeded since it was first mapped to chromosome arm 17q in 1990 (4, 5). A second locus, BRCA2, recently mapped to chromosome arm 13q (6), appears to account for a proportion of earlyonset breast cancer roughly equal to that resulting from BRCA1. Unlike BRCA1, however, BRCA2 may not influence ovarian cancer risk. The remaining susceptibility to early-onset breast cancer is likely attributable to unmapped genes for familial cancer and rare germline mutations in genes such as TP53, which encodes the tumor suppressor protein p53 (7) . It has also been suggested that heterozygote carriers of defective forms of the gene predisposing to ataxia telangiectasia are at higher risk for breast cancer (8, 9). Late-onset breast cancer is often familial in origin, although the risks in relatives are not as high as those for early-onset breast cancer (10, 11 ). The percentage of such cases that are due to genetic susceptibility is unknown.
Like many other genes involved in familial cancer, BRCA1 appears to encode a tumor suppressor, a protein that acts as a negative regulator of tumor growth. Cancer-predisposing alleles typically carry mutations that cause loss or reduction of gene function. Predisposition to cancer is inherited as a dominant genetic trait, whereas the predisposing allele generally behaves as a recessive allele in somatic cells. Thus, a single inherited copy of the mutant allele causes predisposition, and loss or inactivation of the wild-type allele completes one of the steps in progression toward malignancy. When chromosome loss is observed in breast and ovarian tumors from patients who carry BRCA1 predisposing alleles, the wild-type copy of BRCA1 is invariably lost while the presumptive mutant allele is retained (12) (13) (14) . This finding supports the hypothesis that BRCA1 is a tumor suppressor gene and suggests that the functional BRCA1 protein is present in normal breast and ovarian epithelium tissue and is altered, reduced, or absent in some breast and ovarian tumors.
Genetic analysis of recombinant chromosomes in members of large kindreds allowed localization of BRCA1 initially to a region of 1 to 2 megabases on chromosome 17q (15-17) and, subsequently, to a region of about 600 kilobase pairs (kb) (18) between markers D17S1321 and D17S1325 (19) . A physical map comprised of overlapping yeast artificial chromosomes (YACs), Pl, bacterial artificial chromosomes (BACs), and cosmid clones was generated for this region (18) .
Identification of a strong BRCA1 candidate gene. Several strategies were used to develop a detailed map of transcripts for the 600-kb region of 17q2l between D17S1321 and DJ 7S1 325. Sixty-five candidate expressed sequences (20) within this region were identified. Expressed sequences were characterized by DNA sequence, database comparison, transcript size, expression pattern, genomic structure and, most importantly, DNA sequence analysis in individuals from kindreds that segregate 17q-linked breast and ovarian cancer susceptibility. Three expressed sequences eventually were merged into a single transcription unit whose characteristics strongly suggest that it is BRCAI (21). This transcription unit is located in the center of the 600-kb region (Fig. 1) Fig. 2A) . Smith-Waterman (23) and BLAST (24) searches identified a sequence near the NH2-terminus that has considerable similarity to zinc finger domains (25) (Fig. 2B ). This sequence contains cystine and histidine residues present in the consensus Cys3-His-Cys4 (C3HC4) zinc finger motif and shares many other residues with zinc finger proteins in the databases. The BRCA1 gene is composed of 22 coding exons distributed over roughly 100 kb of genomic DNA (Fig. 3) . Hybridization of RNA blots to labeled fragments of BRCA1 cDNA revealed a single transcript of 7.8 kb. This transcript is most abundant in testis and thymus, but is also present in breast and ovary (Fig. 4) . The cDNA clones derived from the 5' onethird of BRCA1 transcripts display a complex pattem of altemative splicing. Four altemative splices were observed downstream of the start codon as independent cDNA clones (P3, P4, B31, and B21 in ing is coordinated with alternative splicing farther downstream, and whether all the splice variants produce proteins with an identical NH2-terminus, are questions that remain to be explored.
We also probed genomic DNA samples from several different species with BRCA1 sequences devoid of the zinc finger region. Low-stringency blots revealed strongly hybridizing fragments in tissues from humans, mice, rats, rabbits, sheep, and pigs, but not chickens (Fig. 5) (Table 2 The missense mutation observed in kindred 2099 is potentially disruptive as it substitutes a large, charged amino acid (Arg) for a small, hydrophobic amino acid (Met). Five common polymorphisms were also identified in the BRCAI coding sequence (Table 3) .
CPICLELIKEPVSTK-CDHIFCKFCMLKLLNQKK---GPSQCPLCK RPT1 CPICLELLKEPVSAD-CNHSFCRACITLNYESNRNTDGKGNCPVCR RIN1 CPICLDMLKNTMTTKECLHRFCSDCIVTALRS-----GNKECPTCR RFP1 CPVCLQYFAEPMMLD-CGHNICCACLARCWGTAC---TNVSCPQCR C3HC4 motif C--C------------C-H--C--C----------------
The individual studied in kindred 2035 is likely to carry a regulatory mutation in BRCAI. In her cDNA, two polymorphic sites (PM1 and PM7) appeared homozygous, whereas her genomic DNA revealed heterozygosity at these positions (Fig. 6C) . One possible explanation for this observation is that mRNA from her mutant BRCAI allele is absent because of a mutation that affects RNA production or stability. We explored this possibility further by examining three additional polymorphic sites (PM6, PM7, and PM2) in the BRCAI including both carriers and noncarriers of the predisposing haplotype (Fig. 6) . In each kindred, the corresponding mutant allele was detected only in individuals carrying the BRCAI-associated haplotype. In the case of the potential regulatory mutation in kindred 2035, cDNA and genomic DNA from carriers in the kindred were compared for heterozygosity at polymorphic sites. In every instance, the extinguished allele in the cDNA sample was shown to lie on the chromosome that carries the BRCAI predisposing allele.
To exclude the possibility that the mutations were simply common polymorphisms in the population, we used allelespecific oligonucleotides (ASOs) for each mutation to screen a set of control DNA samples (27). The actual mutation in kindred 2035 has not been identified, so we could not determine its frequency in the general population. Gene frequency estimates in Caucasians were based on random samples from the Utah population. Gene frequency estimates in African Americans (17) . This difference in age of onset could be due to an ascertainment bias in the smaller, more highly penetrant families, or it could reflect tissue-specific differences in the behavior of BRCAI mutations. The other four kindreds that segregate known BRCA1 mutations have, on average, 1 ovarian cancer for every 10 cases of breast cancer, but have a high proportion of breast cancer cases diagnosed at an early age (late 20s or early 30s). Kindred 1910, which has a 1-bp insertion mutation, is noteworthy because three of the four affected individuals had bilateral breast cancer, and in each case the second tumor was diagnosed within a year of the first occurrence. Kindred 2035, which segregates the potential regulatory BRCA1 mutation, might also be expected to have a 
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whose early-onset breast or ovarian cancer was not ascertained by family history supports the view that many early-onset cases are due to mutations at the BRCAI locus (38) . The role of BRCAI in cancer progression may now be addressed with molecular precision. The large size and fragmented nature of the coding sequence will make exhaustive searches for new mutations challenging. Nevertheless, the percentage of total breast and ovarian cancer caused by mutant BRCAI alleles will soon be estimated, and individual mutation frequencies and penetrances may be established. This in turn may permit accurate genetic screening for predisposition to a common, deadly disease. Although such research represents an advance in medical and biological knowledge, it also raises numerous ethical and practical issues, both scientific and social, that must be addressed by the medical community.
Note (43) , and subjected to electrophoresis on 6% polyacrylamide gels. Polymorphisms were initially detected by eye on both strands and subsequently confirmed by ASO analysis (27). 27. PCR products were generated as described (26) and quantified after electrophoresis through 2% agarose gels containing ethidium bromide by comparison with DNA standards. PCR product (10 pl) was added to 110 ,ll of denaturant (7.5 ml of H20, 6.0 ml of 1 N NaOH, 1.5 ml of 0.1% bromophenol blue, and 75 ml of 0.5 mM EDTA) and incubated for 10 min at room temperature. Samples (30 pl) were then blotted onto Hybond membrane (Amersham) with a dot-blotting apparatus (Gibco-BRL). The DNA was fixed on the membrane by exposure to ultraviolet light (Stratagene 
